Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.
Cardiovascular outcome trials (CVOTs) in patients living with T2DM have confirmed that GLP-1R agonists decrease cardiovascular mortality and reduce the incidence of myocardial infarction (MI) and stroke.
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated. Given emerging evidence of both metabolic and direct cardiovascular actions, a comprehensive synthesis of cardiovascular outcome trial data is required to clarify ...
This overview summarizes the experimental and clinical evidence of cardiovascular risk reduction offered by GLP-1 RA, and provides practical information on how these drugs should be implemented in the treatment of type 2 diabetes in the cardiology community.
Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines.
Those who took a GLP-1 drug like Ozempic or Mounjaro showed 13% less risk of experiencing heart attacks and other major cardiovascular events over the course of nearly three years of use.
Mechanistically, GLP-1 receptors on vascular endothelium and neural tissue appear to influence oxidative stress, mitochondrial function, and neuroinflammation.5 Translating that biology into acute neuroprotection has proven harder.
